Physalin B Suppresses Inflammatory Response to Lipopolysaccharide in RAW264.7 Cells by Inhibiting NF-κB Signaling

Journal of Chemistry, Jun 2018

Physalin B from Physalis angulata L. (Solanaceae) is a naturally occurring secosteroid with multiple biological activities. But its anti-inflammatory activity and mechanism remain unclear. Physalin B effects on RAW264.7 macrophages stimulated by lipopolysaccharide (LPS) were observed in this study. The expression and secretion of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) induced by LPS were significantly inhibited by physalin B. Meanwhile, the NF-κB nuclear translocation induced by LPS was inhibited by physalin B. The anti-inflammatory effects of physalin B could not be inhibited by mifepristone (RU486), the blocker of glucocorticoid receptor. In conclusion, physalin B can suppress inflammatory response to LPS in macrophages by inhibiting the production of inflammatory cytokines via NF-κB signaling.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://downloads.hindawi.com/journals/jchem/2018/7943140.pdf

Physalin B Suppresses Inflammatory Response to Lipopolysaccharide in RAW264.7 Cells by Inhibiting NF-κB Signaling

Hindawi Journal of Chemistry Volume 2018 Physalin B Suppresses Inflammatory Response to Lipopolysaccharide in RAW264.7 Cells by Inhibiting NF-?B Signaling Yanjun Yang Lang Yi 0 1 Qing Wang 1 Bingbing Xie 1 Congwei Sha 2 Yan Dong Gabriel Navarrete-Vazquez 0 Department of Pharmacy, Guangdong Food and Drug Vocational College , Tianhe District, Guangzhou 510520 , China 1 Department of Immunology, Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine , Baiyun District, Guangzhou 510405 , China 2 Guangdong Provincial Institute of Biological Products and Materia Medica , Baiyun District, Guangzhou 510440 , China Physalin B from Physalis angulata L. (Solanaceae) is a naturally occurring secosteroid with multiple biological activities. But its anti-inflammatory activity and mechanism remain unclear. Physalin B effects on RAW264.7 macrophages stimulated by lipopolysaccharide (LPS) were observed in this study. 0e expression and secretion of tumor necrosis factor-? (TNF-?) and interleukin-6 (IL-6) induced by LPS were significantly inhibited by physalin B. Meanwhile, the NF-?B nuclear translocation induced by LPS was inhibited by physalin B. 0e anti-inflammatory effects of physalin B could not be inhibited by mifepristone (RU486), the blocker of glucocorticoid receptor. In conclusion, physalin B can suppress inflammatory response to LPS in macrophages by inhibiting the production of inflammatory cytokines via NF-?B signaling. 1. Introduction Inflammation is a fundamental pathological phenomenon and a complex biological response participating in the development of diverse diseases [ 1?4 ]. Inflammation is usually mediated by eicosanoids and cytokines released by injured or infected cells, especially activated immunocytes. TNF-? and IL-6 are key inflammatory cytokines in macrophages activated by LPS [ 5, 6 ]. Although helpful to combat against infection, vigorous inflammatory cytokines may lead to edema, cellular metabolic stress, and tissue necrosis. NF-?B, an immediate early transcriptional activator, plays a central role in inflammatory response by binding with the promoters to induce transcription of proinflammatory genes, such as TNF-? and IFN-c [ 7 ]. NF-?B signaling is well known to be involved in various diseases, including inflammation and cancers, and thus has attracted attention as a drug target [ 8 ]. Physalin B, a naturally occurring secosteroid isolated from the stems and aerial parts of Physalis angulata L. (Solanaceae) (Figure 1), possesses a unique 13,14-seco16,24-cycloergostane skeleton, an H-ring with a C14?O?C27 bond and a cage-shaped structure, with a highly oxygenated, complex structure similar to glucocorticoid. In addition to the intriguing structure, there is considerable interest in the biological activities of physalin B. In the experiments in vivo, the physalin B anti-inflammatory effect appeared to be mostly due to the activation of glucocorticoid receptors, which represented novel therapeutic options for the treatment of inflammatory diseases [ 9 ]. Physalin B was thought to have the potential to be an effective chemotherapeutic lead compound for the treatment of malignant melanoma [ 10 ]. It showed strong cytotoxicity against multiple tumor cell lines [ 11 ] and antimitotic activity for the first cleavage [ 12 ] and inhibited the growth of several human leukemia cells [ 13 ]. Physalin B was considered responsible for the antimicrobial activity, at the concentration of 200 ?g/ml, and physalin B exhibited about 85% of the inhibitory activity observed with the mixture of physalins (pool) containing physalins B, D, F, and G, at the 3O 12 same concentration [ 14 ]. Physalin B exhibited a minimum inhibitory concentration (MIC) value (128 ?g/ml) against Mycobacterium tuberculosis H37Rv strain [ 15 ]. ?us, physalin B has the potential to regulate a broad range of biological events. However, the underlying mechanisms of physalin B remain largely unknown. ?is study observed the anti-in?ammatory underlying mechanism of physalin B in RAW264.7 macrophages stimulated by LPS. ?e roles of the nuclear factor kappa B (NF-?B) and the glucocorticoid receptor in physalin B antiin?ammatory e?ect were analyzed. ?e study might provide evidence for physalin B as the lead structure of antiin?ammatory drugs. 2. Materials and Methods 2.1. Plant Material. Physalin B was isolated from Physalis angulata (Physalis angulata L.). ?e herb was collected from Puning in Guangdong Province by Mr. Wen-Biao Chen and identi?ed by Dr. Qing-Qian Zeng. ?e specimens (GICMM number 5) were stored in the Guangdong Institute of Chinese Materia Medica. 2.2. Chemicals and Reagents. ?e isolated compound was analyzed by HR mass spectrometry, and its purity was found to be 100% for small-molecule single-crystal X-ray diffraction analysis. LPS (from Escherichia coli 0111 : B4) was purchased from Sigma (St. Louis, USA). ?e monoclonal antibodies I?B (4814S), NF-?B p65 (6956S), and ?-actin (2118S) were purchased from Cell Signaling Technology (CST, USA). Mouse TNF-? (E09483-1643) and IL-6 (E093621643) ELISA detection kits were purchased from eBioscience (California, USA). TRIzol (15596026) was purchased from Invitrogen. Reverse Transcription Kit (135600) and SYBR Green Quantitative PCR Kit (262000) were purchased from Toyobo (Osaka, Japan). ?e ECL chemiluminescence detection kit was purchased from ?ermo (Waltham, MA, USA). 2.3. Isolation and Purication of Physalin B. ?e air-dried and milled whole plants of P. angulata (8 kg) were extracted with ethanol (85%) three times (3 ? 30 L) under immersion, for 1 week each. After ?ltration and evaporation of the solvent under reduced pressure, the combined crude ethanolic extract (1067 g) was mashed and then dissolved successively with petroleum ether, EtoAc, and n-BuOH to a?ord dried petroleum ether-soluble (101 g), EtoAc-soluble (49 g), and nBuOH-soluble (48 g) fractions, respectively. Accordingly, the EtoAc-soluble extract was subjected to medium-pressure column chromatography over silica gel (LC60A 40?63 micron) and eluted using a step gradient of a petroleum ether and EtoAc solvent system (100 : 0, 100 : 1, 80 : 1, 50 : 1, 25 : 1, 10 : 1, 5 : 1, 3 : 1, 2 : 1, 1 : 1) at a ?ow rate of 50 ml?min?1, pressure 20 bar, to obtain ten fractions (F1?F10) based on the TLC pro?le. Each fraction was concentrated in vacuo. Further puri?cation of subfraction F7 (petroleum ether and EtoAc solvent system: 5 : 1) by repeated column chromatography over silica gel (LC60A 40?63 micron) with petroleum etherEtoAc (100 : 0 to 1 : 1) followed by thin-layer chromatography gave transparent crystals, physalin B, suitable for X-ray diffraction analysis (80.0 mg). Physalin B, colorless prismatic crystals (petroleum etherEtoAc), mp253-254?C. HR-EI: m/z 510.1883(C28H30O9, calcd. for 510.1884), 1H-NMR (400 MHz, acetone-d6)?: 6.92 (1H, m, H-3), 6.50(1H, s, 13-OH), 5.86(1H, dd, J 10.4, 2 Hz, H-2), 5.61 (1H, brd, J 6 Hz, H-6), 4.56(1H, brs, H-22), 4.40 (1H, dd, J 13.6, 4.6 Hz, H-27), 3.76(1H, d, J 13.6, H-27), 1.88(3H, s, CH3-21), 1.31(3H, s, CH3-28), 1.19 (3H, s, CH319).13C-NMR (100 MHz, acetone-d6)?: 205.3(C-1), 127.7 (C-2), 147.3(C-3), 33.3(C-4), 136.2(C-5), 124.7(C-6), 25.4 (C-7), 41.1(C-8), 34.4(C-9), 53.6(C-10), 25.2(C-11), 26.3 (C-12), 80.0(C-13), 107.8(C-14), 209.7(C-15), 56.1(C-16), 81.9(C-17), 172.7(C-18), 17.6(C-19), 81.5(C-20), 22.0(C-21), 77.6(C-22), 32.8(C-23), 31.6(C-24), 50.9(C-26), 167.5(C-26), 61.7(C-27), 25.6(C-28). 2.4. Cell Culture. ?e culture of RAW264.7 cells was obtained the way we had established in our lab [ 16 ]. 2.5. Cell Viability. RAW264.7 cells (1 ? 105/ml) were seeded in a 96-well plate and incubated at 37?C overnight. Cells were stimulated with various concentrations of physalin B for 24 h, and PBS was used as vehicle control. At the end of the incubation, 10 ?l of MTT (5 mg/ml in PBS) solution was added and incubated for an additional 2 h. After DMSO solubilized the formazan crystals, it was measured using an enzyme-linked immunosorbent assay (Molecular Devices, Sunnyvale, CA) at 595 nm. ?e relative cell viability was calculated and compared with the absorbance of the untreated control group. 2.6. Detection of TNF-? and IL-6 Release. RAW264.7 cells were treated with positive drug (1 ?M dexamethasone) or di?erent concentrations of physalin B (20, 10, and 5 ?M) for 2 h and then stimulated with 1 ?g/ml LPS for 8 h. PBS was used as the control. After the incubation, the culture supernatant was collected. Concentration of in?ammatory cytokines (TNF-? and IL-6) was analyzed by ELISA. 3 n o i s se2 r p x e A N R1 m 6 L I 0 6000 ? ? 2.7. Real-Time PCR for TNF-? and IL-6 Assay. RNA was extracted from RAW264.7 cells by TRIzol method. cDNA synthesis and the quantitative PCR were obtained as described in the previous study of our lab [ 17 ]. 2.8. Western Blotting for I?B? and NF-?B p65 Protein Assay. For Western blotting assay, we used KeyGEN Nuclear and Cytoplasmic Protein Extraction Kit to extract NF-?B p65 and I?B? protein and BCA protein assay kit to measure the protein concentrations. Protein samples (50 ?g) were fractionated by 10% SDS-PAGE and transferred onto PVDF membranes (Bio-Rad). Nonspeci?c reactivity was blocked by 5% BSA for 2 h at room temperature, followed by primary antibodies for anti-mouse NF-?B p65, I?B?, GAPDH diluted to 1 : 1000 and then by goat anti-mouse HRP-conjugated secondary antibody at 1 : 15000. ?e speci?c proteins were ? ? ? ? ? ? ? ?? ?? ? ? ? ? ? ? ? ?? ?? l o r t n o C l o r t n o C ? M ? 5 M ? 5 u R + M ? 5 u R + M ? 5 M ? 0 1 M ? 0 1 u R + M ? 0 1 u R + M ? 0 1 M ? 0 2 M ? 0 2 u R + M ? 0 2 u R + M ? 0 2 3 n o i s2 s e r p x e A N R1 m 6 L I 0 M ? 0 1 M ? 0 2 detected by exposing membranes to Kodak X-Omat ?lms, and densitometric analysis was performed by using the Quantity One to scan the signals. 2.9. Statistical Analysis. Results were showed as mean ? SEM. One-way analysis of variance (ANOVA) and Tukey multiple comparison tests were used to analyze the data. P < 0.05 was considered statistically signi?cant. All analyses were performed using SPSS 13.0 for Windows. 3. Results and Discussion 3.2. E?ect of Physalin B on the mRNA and Protein Levels of TNF-? and IL-6. In order to evaluate the e?ect of physalin B on LPS stimulation, ELISA was used for determining the levels of in?ammatory cytokines IL-6 and TNF-?. LPS (1 ?g/ml) signi?cantly increased the mRNA and protein levels of TNF-? and IL-6. However, dexamethasone (1 ?M) signi?cantly inhibited the mRNA and protein levels of TNF-? and IL-6 (P < 0.01). Physalin B decreased TNF-? and IL-6 mRNA and protein levels signi?cantly at 5, 10, and 20 ?M in a concentration-dependent manner (P < 0.05 or P < 0.01) (Figure 3). 3.1. Cell Viability. In order to determine the working concentration of physalin B, RAW264.7 cells were treated with 12.5, 25, and 50 ?M physalin B. We found that physalin B at 50 ?M can markedly reduced the cell viability of RAW264.7 cells compared with control (P < 0.01), but others did not show any signi?cant di?erence (Figure 2). 3.3. ?e E?ect of GR Antagonist on the Inhibition of TNF-? and IL-6 Expression by Physalin B. To analyze whether the anti-in?ammatory e?ect of physalin B relied on the glucocorticoid receptor (GR), we chose the GR selective antagonist mifepristone (RU486). Our study showed that RU486 did not inhibit the e?ect of physalin B on the levels of TNF-? and IL-6 Control LPS 5 ?M 10 ?M 20 ?M mRNA and protein (P > 0.05) in contrast to dexamethasone (Figure 4). 3.4. ?e E?ects of Physalin B on I?B and NF-?B/p65 Protein Level. Stimulation with LPS caused I?B decreasing in cytoplasm and NF-?B p65 increasing in nucleus. However, when the cells were pretreated with physalin B, the LPS e?ect on I?B and NF-?B p65 was reversed. Our data revealed that, in the cells cotreated with LPS and physalin B, the LPSinduced p65 was suppressed. ?ese results demonstrated that physalin B could inhibit NF-?B activation. Physalins share a unique 13,14-seco-16,24-cycloergostane skeleton, with a highly oxygenated and complex structure. Type B physalins, such as physalin B, have an H-ring with a C14?O?C27 bond and a cage-shaped structure. ?e AB-ring of physalins that is commonly found in plant steroids was suggested to be involved in biological activities. For instance, Ma and coworkers suggested that the A-ring of physalin A could form a covalent bond with cysteine residues of IKK? [ 18 ]. In contrast, little attention was paid to the contribution of the cage-shaped right-sided structure in Type B physalins (e.g., physalin B). Masaki et al. [ 19 ] hypothesized that the unique partial structure would play an important role in the biological activity. Also, physalin B has a similar glucocorticoid structure. Glucocorticoids have anti-in?ammatory activities with many adverse e?ects, such as osteoporosis, metabolic diseases, high blood pressure, and so on. From our results, physalin B signi?cantly inhibited the mRNA expression and secretion of TNF-? and IL-6 in macrophages induced by LPS at the concentrations without obvious cytotoxicity (Figures 2 and 3). In addition, the results showed that RU486 inhibited the anti-in?ammatory e?ects of dexamethasone, but not physalin B in RAW264.7 cells (Figure 4). It suggests that physalin B does not require GR for the anti-in?ammatory activity in vitro, which is di?erent from Vieira?s research [ 9 ]. Physalin B, although with secosteroidal chemical structure, did not act through the glucocorticoid receptor in macrophages, which means its structure group di?erent from glucocorticoid is the active core. NF-?B, an immediate early transcriptional activator, participates in in?ammatory responses and acute phase through increasing the expression of immediate early in?ammatory genes by binding with the promoters, including TNF-?, IFN-c, NOS II, ICAM, and so on [ 20 ]. I?B? is the main regulator of NF-?B, and NF-?B combined with I?B? is inactivated [ 21 ]. When I?B? is degraded in cytoplasm, NF?B can translocate to the nucleus and transcriptional activation is activated. From the results (Figure 5), the decreased I?B? protein level in cytoplasm and the increased NF-?B p65 protein level in nucleoprotein induced by LPS were reversed by physalin B. ?ese results provide evidence that physalin B exerts anti-in?ammatory e?ect by inhibiting NF-?B activation. 4. Conclusions Physalin B, a naturally occurring secosteroid from Physalis angulata L., can inhibit in?ammatory response in LPS-induced macrophages by inhibiting NF-?B activation in vitro. Its antiin?ammatory e?ect is independent on the glucocorticoid receptor. Our study suggests that physalin B could be a potential new therapeutic agent against in?ammation. Data Availability 0e data used to support the findings of this study are available from the corresponding author upon request. Conflicts of Interest 0e authors declare that none of the authors has any kind of conflicts of interest related to the present work. Authors? Contributions Lang Yi, Qing Wang, and Bingbing Xie performed the cellbased assay experiments. Yanjun Yang and Congwei Sha performed the isolation and purification of physalin B. Yanjun Yang drafted the manuscript. Yanjun Yang and Yan Dong supervised and coordinated the study and revised the manuscript. Acknowledgments 0e authors acknowledge the financial support from the project supported by the Natural Science Foundation of Guangdong (S2013010013484) and Science and Technology Project of Guangdong (2014A020210016 and 2011B031700072). Journal of Nanomaterials Advances in Physical Chemistry Hindawi www.hindawi.com Bioin organic Chemistry and Applicatio Hindawi www.hindawi.com i Journal of Photoenergy Hindawi www.hindawi.com Hindawi Publishing Corporation hwtwpw:/.hwinwdwa.hi.ncodmawi.com Hindawi www.hindawi.com Hindawi ology Hindawi www.hindawi.com Journal of Chemistry Hindawi www.hindawi.com International Journal of Electrochemistry Hindawi www.hindawi.com Hindawi www.hindawi.com Hindawi www.hindawi.com International Journal of Analytical Chemistry Hindawi www.hindawi.com Journal of Hindawi www.hindawi.com [1] A. Minagar , P. Shapshak , R. Fujimura , R. Ownby , M. Heyes , and C. Eisdorfer , ? 0e role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV associated dementia, Alzheimer disease , and multiple sclerosis, ? Journal of the Neurological Sciences , vol. 202 , no. 1-2 , pp. 13 - 23 , 2002 . [2] M. Feldmann , ? Development of anti-TNF therapy for rheumatoid arthritis,? Nature Reviews Immunology , vol. 2 , no. 5 , pp. 364 - 371 , 2002 . [3] P. Rutgeerts , G. Assche, and S. Vermeire , ? Review article: infliximab therapy for inflammatory bowel disease-seven years on,? Alimentary Pharmacology and >erapeutics , vol. 23 , no. 4 , pp. 451 - 463 , 2006 . [4] L. Minghetti , ? Role of inflammation in neurodegenerative diseases,? Current Opinion in Neurology , vol. 18 , no. 3 , pp. 315 - 321 , 2006 . [5] Y. Wang , C. Yu , Y. Pan et al., ?A novel compound c12 inhibits inflammatory cytokine production and protects from inflammatory injury in vivo,? PLoS One , vol. 6 , no. 9 , article e24377 , 2011 . [6] T. Smallie , G. Ricchetti, N. J. Horwood , M. Feldmann , A. R. Clark , and L. M. Williams , ?IL- 10 inhibits transcription elongation of the human TNF gene in primary macrophages , ? Journal of Experimental Medicine , vol. 207 , no. 10 , pp. 2081 - 2088 , 2010 . [7] P. Viatour , M. Merville , V. Bours , and A. Chariot , ? Phosphorylation of NF-kB and IkB proteins: implications in cancer and inflammation,? Trends Biochemical Sciences , vol. 30 , no. 1 , pp. 43 - 52 , 2005 . [8] A. Hoffmann and D. Baltimore , ? Circuitry of nuclear factor ?B signaling,? Immunological Reviews , vol. 210 , no. 1 , pp. 171 - 186 , 2006 . [9] V. T. Angelica , P. Vanessa , L. B. Lucilia , S. Cristoforo , R. M. Ivone , and T. 0erezinha , ? Mechanisms of the antiinflammatory effects of the natural secosteroids physalins in a model of intestinal ischaemia and reperfusion injury ,? British Journal of Pharmacology , vol. 146 , no. 2 , pp. 244 - 251 , 2005 . [10] C.-C. Hsu , Y.-C. Wua , L. Farh et al., ? Physalin B from Physalis angulata triggers the NOXA-related apoptosis pathway of human melanoma A375 cells,? Food and Chemical Toxicology , vol. 50 , no. 3-4 , pp. 619 - 624 , 2012 . [11] P.-C. Kuo , T.-H. Kuo , A.G. Damu et al., ?Physanolide A novel skeleton steroid, and other cytotoxic principles from Physalis angulata , ? Organic Letters , vol. 14 , no. 8 , pp. 2953 - 2956 , 2006 . [12] H. I. F. Magalh?es , M. L. Veras , O. D. L. Pessoa et al., ? Preliminary investigation of structure-activity relationship of cytotoxic physalins,? Letters in Drug Design and Discovery , vol. 3 , no. 1 , pp. 9 - 13 , 2006 . [13] C. H. Chiang , M. S. Jaw , and M. P. Chieng , ? Inhibitory effects of physalin B and physalin F on various human leukemia cells in vitro , ? Anticancer Research , vol. 12 , no. 4 , p. 1155 , 1992 . [14] S. T. G. Melissa , S. M. Sonia , B. G. F. M. Terezinha , C. Paola , and T. C. B. 0erezinha , ? Studies on antimicrobial activity, in vitro, of Physalis angulata L. (Solanaceae) fraction and physalin B bringing out the importance of assay determination,? Memo?rias do Instituto Oswaldo Cruz , vol. 100 , no. 7 , pp. 779 - 782 , 2005 . [15] H. Janua ?rio, E. Rodrigues Filho, R. C. L. R. Pietro , S. Kashima , D. N. Sato , and S. C. Franca , ? Antimycobacterial physalins from Physalis angulata L. (Solanaceae) , ? Phytotherapy Research , vol. 16 , no. 5 , pp. 445 - 448 , 2002 . [16] L. Yi , J.-F. Luo , B. -B. Xie et al., ?Alpha7 nicotinic acetylcholine receptor is a novel mediator of sinomenine anti-inflammation effect in macrophages stimulated by Lipopolysaccharide,? Shock , vol. 44 , no. 2 , pp. 188 - 195 , 2015 . [17] Y.-J. Yang , L. Yi , Q. Wang , B.-B. Xie , Y. Dong , and C.-W. Sha, ? Anti-inflammatory effects of physalin B from Physalis angulata on lipopolysaccharide-stimulated RAW 264.7 cells through inhibition of NF-?B pathway , ? Immunopharmacology and Immunotoxicology , vol. 39 , no. 2 , pp. 74 - 79 , 2017 . [18] L. Ji , Y. Yuan , L. Luo et al., ?Physalins with anti-inflammatory activity are present in Physalis alkekengi var. franchetii and can function as Michael reaction acceptors , ? Steroids , vol. 77 , no. 5 , pp. 441 - 447 , 2012 . [19] M. Masaki , K. Shuntaro , O. Megumi et al., ?Synthesis of the right-side structure of type B physalins ,? Israel Journal of Chemistry , vol. 57 , no. 3-4 , pp. 309 - 318 , 2017 . [20] T. G . Erkel, ? A new inhibitor of inflammatory signal transduction pathways from a Trichosporiella species , ? FEBS Letters , vol. 477 , no. 3 , pp. 219 - 223 , 2000 . [21] A. L. Solt and J. M. May , ? 0e IkappaB kinase complex: master regulator of NF-?B signaling , ? Immunologic Research , vol. 42 , no. 1-3 , pp. 3 - 18 , 2008 .


This is a preview of a remote PDF: http://downloads.hindawi.com/journals/jchem/2018/7943140.pdf

Yanjun Yang, Lang Yi, Qing Wang, Bingbing Xie, Congwei Sha, Yan Dong. Physalin B Suppresses Inflammatory Response to Lipopolysaccharide in RAW264.7 Cells by Inhibiting NF-κB Signaling, Journal of Chemistry, 2018, DOI: 10.1155/2018/7943140